MRK - Dosing underway in OncoSec's Tavo combo trial in skin cancer

OncoSec Medical ([[ONCS]] +1.4%) announces that the first patient was dosed in its investigator-initiated OMS-104 Phase 2 trial evaluating Tavo (tavokinogene telseplasmid) in patients with operable, locally or regionally advanced melanoma, a type of skin cancer.The study aims to evaluate TAVO in combination with Bristol Myers Squibb's ([[BMY]] +0.4%) anti-PD-1 checkpoint inhibitor OPDIVO (nivolumab) as a neoadjuvant therapy prior to surgery in patients with operable, locally or regionally advanced melanoma.The trial is designed to evaluate if the addition of TAVO can improve clinical outcomes already observed when using nivolumab alone as a neoadjuvant therapy.The primary endpoint of the study is pathological complete response, estimated based on the proportion of participants with no viable tumor on histologic assessment at definitive surgery after the 12-week neoadjuvant period.TAVO in combination with Merck's ([[MRK]] -1.4%) KEYTRUDA (pembrolizumab), has already shown enhanced overall response rate and partial tumor responses in patients with anti-PD-1 checkpoint-refractory metastatic melanoma in OncoSec's KEYNOTE-695 registration

For further details see:

Dosing underway in OncoSec's Tavo combo trial in skin cancer